Noxopharm Limited’s Post

View organization page for Noxopharm Limited, graphic

1,239 followers

Proactive’s Tylah Tully details Noxopharm’s new phase 1 HERACLES study in the latest Just The Facts. The company is seeking to shift the treatment paradigm for autoimmune diseases and especially lupus, advancing its SOF-SKN first-in-class oligonucleotide TLR7/8 antagonist in a bid to fully treat the disease, rather than just manage symptoms. https://lnkd.in/gQ-MnTdn

Just the Facts: Noxopharm

Just the Facts: Noxopharm

proactiveinvestors.com.au

To view or add a comment, sign in

Explore topics